36.6 F
New York
Wednesday, January 27, 2021

AstraZeneca’s [NYSE: AZN] Lynparza Shows Positive Result In BRCA-Mutated Ovarian Cancer

Must read

JPMorgan [NYSE: JPM] Announced To Initiate A Digital Retail Bank In The United Kingdom

JPMorgan Chase revealed that the company will launch a new digital retail bank in the United Kingdom offering the customer of the region...

Humanigen [NASDAQ: HGEN] Announces Expansion Of Manufacturing Agreement With Ajinomoto Bio-Pharma

Humanigen Inc revealed that the company has extended the manufacturing agreement with  Ajinomoto BioPharma to support the fill-finish of Lenzilumab. The Lenzilumab is...

Synchrony [NYSE: SYF] Announced To Purchase Allegro Credit

Synchrony Financials revealed that the company entered into a definitive contract to Purchase Allegro Credit. Allegro Credit's customer base and merchant network will...

Vericel Corp [NASDAQ: VCEL] Names Joe Mara As The New CFO

Vericel Corporation revealed that the company has named Joe Mara as the CFO of the company. He has over more than 20 years...

AstraZeneca PLC [NYSE: AZN] revealed Friday that Lynparza has shown a long-term progression-free survival (PFS) benefit versus placebo in patients with newly diagnosed BRCA-mutated Ovarian Cancer.

If we look at the statistics of cancer, ovarian cancer is considered to be the eighth most common cause of death in women. In 2018, approximately 300,000 new patients have diagnosed with this disease and almost 185,000 have lost their lives.

Five-year follow-up data from the Phase III SOLO-1 trial has revealed that LYNPARZA decreased the risk of disease progression or death by 67%.

Shares of AstraZeneca traded up 1.47% as it gained +0.81 on Thursday. This company had recorded a trading volume of 3.99 million as compared to the average volume of 6.65 million.

Looking at its profitability, it has a return on assets (ROA) of 3.60%, returns on equity (ROE) is 17.80%. Its return on investment (ROI) is 8.30%.

If we turn our focus on its liquidity, it has a current ratio of 0.80. AstraZeneca market capitalization has remained high, hitting $148.04 billion at the time of writing.

In the past 52-weeks of trading, AZN has experienced the 52 weeks low range of $36.15 & a high range of $64.94. It has traded up 54.74% from its 52-weeks low and traded down -13.86% from its 52-weeks high.

If we look at the data of five years, the company has revealed that 48.3% of patients with the disease were treated with Lynparza have freed from the disease as compared to 20.5% on placebo.

More articles

Latest article

A Paychex [NASDAQ: PAYX] Subsidiary Announces Strategic Collaboration With Zoho Books

SurePayroll, a subsidiary of Paychex company revealed that the company has formed a collaboration with Zoho books. SurePAyroll is a provider of small...

MGP Ingredients [NASDAQ: MGPI] Announced To Acquire Luxco and Its Affiliate Companies

MGP Ingredients  revealed a definitive contract to purchase Luxco, Inc and its affiliated companies. Luxco is an alcohol beverage company with more than 60...

Conformis [NASDAQ: CFMS] Entered A Non-Exclusive agreement with SITES Medical

Conformis Inc revealed that the company inked a development and supply contract with sites medical. Both of the companies will work together to...

Colliers International [NASDAQ: CIGI] Announces Executive Leadership Changes For Australian Business

Colliers International  reported that the company has named Malcom Tyson as the new Chief Executive Officer. He is appointed as the CEO so...

Korn Ferry [NYSE: KFY] Announces Expansion Of Its Footprint In Russian Market

Korn Fery revealed that the company is expanding its footprint in Russia. Moreover, it is adding a high expertise team of executive search...

Haemonetics [NYSE: HAE] To Purchase Cardiva For An Upfront Payment Of $475M

Haemonetics Corporation revealed that the company has inked a definitive contract to purchase Cardiva Medical Inc. Under the contract, Haemontics will pay an...

Philips [NYSE: PHG] To Purchase Capsule Technologies For Cash Consideration Of USD 635M

Koninklijke Philip revealed that the company has inked a contract to purchase Capsule technologies. The company will pay a cash price of $636...

Thermo Fisher Scientific [NYSE: TMO] To Purchase Mesa Biotech For Approx. $450M In Cash

Thermo fisher scientific inc revealed that the company has signed a definitive contract to purchase Mesa Biotech. Thermo will pay a value price...